3 insiders bought €67k of shares over the last 90 days, the latest by James Tobias Hall, filed 06 Oct 2026.
This page follows insider dealings at Integral Diagnostics Limited as filed with ASX, a company from the Health Care sector. From 24 October 2025 to 24 October 2026, the disclosure feed for Integral Diagnostics Limited logged 18 filings by 13 insiders.
No insider sold shares on the market over the period. Instead, the filings list 5 purchases totalling €143k, made by 3 insiders. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 3 senior executives. James Tobias Hall filed the largest purchase, €61k, on 25 June 2026.
Compared with its exchange (1,596 companies, median 4 filings), a count of 18 filings is above the norm. Looking back to 2026, when coverage begins, insiders filed 5 purchases and no sales.
Within a 30-day window, 1 purchase overlapped with buying by a second insider. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 6 October 2026, 18 days ago. The median gap between a trade and its publication by ASX is 3 days. That lag is the time during which only the insider knows about the trade.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Every figure here comes from the filings published by ASX and describes the past, not future prices; it is not investment advice.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended June 2026 · cache
18 of 18 declarations
Integral Diagnostics Limited is a company listed on the XASX, specializing in the provision of medical diagnostic services. It focuses on improving healthcare quality through advanced technologies.
Purchases our model currently ranks for the recommendations list.
All recommendations